DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Samrat Pharmachem Ltd (SAMRATPH) share price today?

Samrat Pharmachem Ltd (SAMRATPH) is trading at ₹271.9 on the BSE, up 6.96% on the day. Source: DocStoX.

What is the PE ratio of Samrat Pharmachem Ltd?

Samrat Pharmachem Ltd has a price-to-earnings (PE) ratio of -32.4 in the Healthcare sector.

What is the market capitalisation of Samrat Pharmachem Ltd?

Samrat Pharmachem Ltd has a market capitalisation of approximately ₹83 crore.

Is Samrat Pharmachem Ltd a profitable company?

Samrat Pharmachem Ltd generates a return on equity of -4.9% with a net profit margin of -1.1%. That is a modest return on shareholder capital.

What is the 52-week high and low of SAMRATPH?

Samrat Pharmachem Ltd (SAMRATPH) has traded between ₹190 and ₹296 over the past 52 weeks, against a current price of ₹271.9.

Does Samrat Pharmachem Ltd pay a dividend?

Yes. Samrat Pharmachem Ltd currently offers a dividend yield of 0.43%. Dividend payments depend on the board's declaration each year.

Samrat Pharmachem Ltd

₹271.90▲ +17.70 (+6.96%)

SAMRATPH·BSE·Healthcare

Market Cap

83.47 Cr

PE Ratio

-32.40

Volume

9,287

Day High - Low

279.60 - 254.20

52W High-Low

296.00 - 190.00

₹271.90▲ +17.70 (+6.96%)

Market Cap83.47 Cr

PE Ratio-32.40

Volume9,287

Day High - Low279.60 - 254.20

52W High-Low296.00 - 190.00

Samrat Pharmachem Ltd (SAMRATPH): company summary

The company's business has deteriorated, with annual net profit swinging from a profit of ₹7 crore to a loss of ₹3 crore.

Samrat Pharmachem Ltd (SAMRATPH) is a micro-cap Healthcare company valued at ₹83 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Samrat Pharmachem Ltd last traded at ₹271.9, sharply up 6.96% on the day.
Recent developments: On 2026-08-19, the company reported positive earnings for the quarter, with net profit reaching ₹87.6 lakh, marking a return to profitability after a period of losses.
Financial performance: The company's business has deteriorated, with annual net profit swinging from a profit of ₹7 crore to a loss of ₹3 crore. The latest quarter saw a turnaround, with net profit turning positive at ₹1 crore, up from a net loss of ₹0 crore a year earlier, though revenue growth slowed to 5.4% compared to the same quarter last year.
Valuation multiples: A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 1.05 times book value.
Things to watch: The company reported a net loss of ₹3 crore in its latest financial year, with net profit margin at -1.1%, down 3.6 percentage points from the prior year. The stock is 14.1% below its 52-week high, and net profit has swung from a profit of ₹17 crore to a loss of ₹3 crore over the past three years.
Where it stands: The company has turned a profit in the latest quarter, but remains in a net loss for the full fiscal year. The most significant movement is the return to profitability in the latest quarter, with net profit rising to ₹1 crore, while annual net profit remains at a loss of ₹3 crore.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

4.7/10

Weak

Fair Value

ROE

-4.86%

Weak

P/E

-32.40x

Loss-making

Debt / Equity

0.16

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

Day₹254.20

₹279.60

52W₹190.00

₹296.00

DocStoX take

Supported by momentum (7.5) and risk (6.1), but held back by quality (1.5). Momentum looks strong at 7.5, but that is offset by quality at 1.5. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

4.7

/10

Weak

Quality

Weak

ROE -4.9%

Valuation

Fair

P/B 1.1× on assets (no earnings to value)

Growth

Slow

Revenue +10.1% 5Y CAGR

Risk

Moderate

D/E 0.16

Momentum

Strong

77% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹272

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹83 Cr

52W High / Low

₹296 / ₹190

Dividend Yield

0.43%

Promoter Holding

49.09%

EPS (TTM)

₹-10.72

Book Value

₹220.67

Key highlights

Low leverage — D/E 0.16
Loss-making — no meaningful P/E
Quality is weak (1.5/10)

1 Positive3 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Samrat Pharmachem Ltd’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Samrat Pharmachem Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Laurus Labs Limited Zydus Lifesciences Limited Apollo Hospitals Enterprise Limited Cipla Limited Dr. Reddy's Laboratories Limited Mankind Pharma Limited Aurobindo Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Samrat Pharmachem Ltd with peers

Samrat Pharmachem Ltd vs Sun Pharmaceutical Industries Limited Samrat Pharmachem Ltd vs Divi's Laboratories Limited Samrat Pharmachem Ltd vs Torrent Pharmaceuticals Limited Samrat Pharmachem Ltd vs Laurus Labs Limited Samrat Pharmachem Ltd vs Zydus Lifesciences Limited Samrat Pharmachem Ltd vs Apollo Hospitals Enterprise Limited

Related tools & concepts

Value Samrat Pharmachem Ltd with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

SAMRATPH newsLatest coverage & filings Open screenerFilter the whole market